Gilead Stops Cancer Drug Trial Early On Positive ResultsNASDAQGilead said an interim analysis of the trial showed patients taking idelalisib plus rituximab with better progression-free survival compared to those receiving rituximab alone. The company s…
Proactive Investors USA & Canada |
Cellmid awarded key European midkine antibodies patent, covers cancer and …
Proactive Investors USA & Canada Maria Halasz, Cellmid’s chief executive officer, commented: “Having patents granted in Europe for our MK antibodies across such a wide array of diseases is a tremendous commercial outcome for Cellmid. “This patent gives Cellmid very clear exclusive … |
Proactive Investors UK |
Cellmid awarded key European midkine antibodies patent, covers cancer and …
Proactive Investors UK Maria Halasz, Cellmid’s chief executive officer, commented: “Having patents granted in Europe for our MK antibodies across such a wide array of diseases is a tremendous commercial outcome for Cellmid. “This patent gives Cellmid very clear exclusive … |
StreetInsider.com (subscription)After-Hours Stock Movers 10/9: (ACUR) (ENZN) (CHTP) Higher; (CTXS) (RT …StreetInsider.com (subscription)This DMC recommendation is based on a predefined interim analysis showing highly statistically significant efficac…
|
Gilead Ends Study of Leukemia Treatment Early After Positive Interim Results
NASDAQ It demonstrated ” highly statistically significant efficacy” in patients receiving the treatment receiving idelalisib plus rituximab compared with those receiving rituximab alone, the company said. The company said it told the Food and Drug … |
Gilead Sciences, Inc. (GILD): Gilead Sciences +3% AH on strong leukemia drug …Seeking Alpha… not fit for chemotherapy will be stopped early based on an analysis showing highly statistically significant efficacy for the primary endpoint of progressi…
UPDATE: Gilead to Stop Phase 3 Study 116 of Idelalisib in Chronic Lymphocytic …BenzingaThis DMC recommendation is based on a predefined interim analysis showing highly statistically significant efficacy for the primary endpoint of progression-free su…
Gilead to Stop Phase 3 Study 116 of Idelalisib in Chronic Lymphocytic Leukemia …Wall Street JournalThis DMC recommendation is based on a predefined interim analysis showing highly statistically significant efficacy for the primary endpoint of progres…
Gilead to Stop Phase 3 Study 116 of Idelalisib in Chronic Lymphocytic Leukemia …MarketWatchThis DMC recommendation is based on a predefined interim analysis showing highly statistically significant efficacy for the primary endpoint of progression-fre…
|
U of S labs look at producing cancer fighting antibodies
News Talk 980 CJME An investment of $1.7 million from the federal government’s Western Economic Diversification (WED) and the provincial government helped the lab buy the necessary infrastructure and tools to create the antibodies at a much larger rate. “Anytime we can … |